Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of compound and its preparation method and application

A compound and catalyst technology, which is applied in the field of bile acid-conjugated pyrroleamide glycogen phosphorylase inhibitors, can solve the problems of direct connection and difficult dissociation of chemical bonds, and achieve the effect of good GP inhibitory activity and favorable activity maintenance.

Active Publication Date: 2016-09-21
SOUTH CHINA UNIV OF TECH
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because most targeting carriers and small molecule drugs cannot be directly connected by chemical bonds, or the chemical bonds formed by the direct connection of the two are difficult to dissociate further, releasing small molecule drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of compound and its preparation method and application
  • A kind of compound and its preparation method and application
  • A kind of compound and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Compound I 1 Preparation

[0041]

[0042] 3α-Methanesulfonyloxy-7α,12α-Dihydroxy-5β-cholestane-24-carboxylic acid methyl ester(III)

[0043] Under ice bath, dissolve methyl cholate (0.19g, 0.66mol) in pyridine (10mL), add p-toluenesulfonyl chloride (97mg, 0.79mmol) and DMAP (97mg, 0.79mmol) with stirring, and stir overnight at room temperature. The next day, it was concentrated under reduced pressure, the residue was diluted with ethyl acetate, washed with saturated brine, and anhydrous Na 2 SO 4 Dry, evaporate the solvent under reduced pressure, flash column chromatography (petroleum ether / ethyl acetate 1 / 1, V / V) to obtain a white solid (1.09 g, 95%). ESI-MS:500.5[M+H] + ; 1 H NMR(400MHz, CDCl 3 )δ: 0.66 (s, 3H), 0.87 (s, 3H), 0.94 (d, J = 6.3 Hz, 3H), 2.38-1.25 (m, 25H), 2.56-2.52 (m, 1H), 2.48 (s ,3H), 3.68(s,3H), 3.84(s,1H), 7.32(d,J=8.0Hz,2H), 7.79(d,J=8.4Hz,2H).

[0044] 3α-hydroxyethoxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylic acid methyl ester (V 1 )

[0045] 3α-...

Embodiment 2

[0051] Compound I 2 Preparation

[0052]

[0053] 3α-(Hydroxyethoxy)ethoxy-7α,12α-Dihydroxy-5β-cholestane-24-carboxylic acid methyl ester (V 2 )

[0054] Refer to the preparation method of 3α-hydroxyethoxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylic acid methyl ester to obtain a white solid (174 mg, 41%). ESI-MS:511.4[M+H] + ; 1 H NMR(400MHz, CDCl 3 )δ:0.62(s,3H),0.85(s,3H),0.91(d,J=6.4Hz,3H),1.97-1.03(m,21H),2.18-2.03(m,5H),3.47-3.45 (m, 2H), 3.65-3.54 (m, 10H).

[0055] 3α-(sulfonyloxyethoxy)ethoxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylic acid methyl ester (VI 2 )

[0056] Refer to the preparation method of 3α-methanesulfonyloxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylate to obtain a white solid (159mg, 51%). ESI-MS: 682.5[M+18] + ; 1 H NMR(400MHz, CDCl 3 )δ:0.62(s,3H),0.84(s,3H),0.91(d,J=6.0Hz,3H),1.96-1.05(m,22H),2.35-2.03(m,4H),2.37(s ,3H),3.65-3.36(m,10H),3.79(s,1H),7.27(d,J=8.0Hz,2H),7.74(d,J=8.0Hz,2H).

[0057] (3α-Oxyethoxyethoxy-cholic acid-yl)-{1-[2-(5-chloro-1H-py...

Embodiment 3

[0060] Compound I 3 Preparation

[0061]

[0062] 3α-[(hydroxyethoxy)ethoxy]ethoxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylic acid methyl ester (V 3 )

[0063] Refer to the preparation method of 3α-hydroxyethoxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylate to obtain a white solid (516 mg, 24%). ESI-MS: 555.5[M+H] + ; 1 H NMR(400MHz, CDCl 3 )δ: 0.62 (s, 3H), 0.84 (s, 3H), 0.91 (d, J = 5.6 Hz, 3H), 1.98-1.01 (m, 21H), 2.30-2.02 (m, 5H), 2.90-2.65 (s,1H),3.66-3.44(m,16H).

[0064] 3α-[(sulfonyloxyethoxy)ethoxy]ethoxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylic acid methyl ester (VI 3 )

[0065] Refer to the preparation method of 3α-methanesulfonyloxy-7α,12α-dihydroxy-5β-cholestane-24-carboxylate to obtain a white solid (870mg, 27%). ESI-MS:726.5[M+18] + ; 1 H NMR(400MHz, CDCl 3 )δ:0.62(s,3H),0.83(s,3H),0.91(d,J=6.0Hz,3H),1.95-1.05(m,22H),2.35-2.03(m,4H),2.38(s ,3H),3.50(s,1H),3.64-3.41(m,14H),3.78(s,1H),7.27(d,J=8.4Hz,2H),7.73(d,J=8.4Hz,2H) .

[0066] (3α-Oxyethoxyethoxyethoxy-cho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound having a structure formula I as shown in the specification, a preparation method and application thereof as well as pharmaceutically acceptable salts or esters of the compound. The compound is a novel cholic acid conjugated pyrrole amide based glycogen phosphorylase inhibitor, can take effect on glycogen phosphorylase of the liver effectively and can function as an optimal medicine for patients with type II diabetes to control blood sugar. The compound can be used for preparing medicines for resisting diabetes and complication thereof, medicines for resisting cardiovascular diseases, medicine for reducing weight and medicines for treating metabolic syndromes.

Description

Technical field [0001] The invention relates to the field of medicinal chemistry, in particular to a new type of cholic acid conjugated pyrrolamide glycogen phosphorylase inhibitor. It also relates to their preparation methods and pharmaceutical compositions containing them. Such compounds can be used to prepare anti-diabetic and its complications drugs, anti-cardiovascular disease drugs, weight-loss drugs, and drugs for treating metabolic syndrome. Background technique [0002] At present, there are more than 92 million diabetic patients in my country, making China the world's largest diabetes country, and about 97% of them are type 2 diabetes. At present, the treatment of type 2 diabetes is divided into insulin and its similar drugs, insulin sensitizers, insulin secretagogues, carbohydrate reducing regulators, etc., according to the different pharmacological action mechanisms of drugs. But these drugs have limited hypoglycemic effect. With the deepening of people's understan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07J43/00A61K31/58A61P3/10A61P3/04A61P3/06A61P9/10A61P9/12A61P3/00
CPCC07J43/003
Inventor 李晶张丽颖张雷吴芳萍
Owner SOUTH CHINA UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com